|
US4714681A
(en)
|
1981-07-01 |
1987-12-22 |
The Board Of Reagents, The University Of Texas System Cancer Center |
Quadroma cells and trioma cells and methods for the production of same
|
|
US4474893A
(en)
|
1981-07-01 |
1984-10-02 |
The University of Texas System Cancer Center |
Recombinant monoclonal antibodies
|
|
US4925648A
(en)
|
1988-07-29 |
1990-05-15 |
Immunomedics, Inc. |
Detection and treatment of infectious and inflammatory lesions
|
|
US5601819A
(en)
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
|
EP0739904A1
(en)
|
1989-06-29 |
1996-10-30 |
Medarex, Inc. |
Bispecific reagents for aids therapy
|
|
DK0553244T4
(da)
|
1990-10-05 |
2005-08-01 |
Celldex Therapeutics Inc |
Målrettet immunostimulering med bispecifikke reagenser
|
|
AU8727291A
(en)
|
1990-10-29 |
1992-06-11 |
Cetus Oncology Corporation |
Bispecific antibodies, method of production, and uses thereof
|
|
EP0582595A1
(en)
|
1991-04-26 |
1994-02-16 |
Surface Active Limited |
Novel antibodies, and methods for their use
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
|
EP1306095A3
(en)
|
1992-03-05 |
2003-06-25 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
ATE139900T1
(de)
|
1992-11-13 |
1996-07-15 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
PT1974747E
(pt)
*
|
1998-08-11 |
2012-09-05 |
Biogen Idec Inc |
Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
|
|
US7090843B1
(en)
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
KR101641345B1
(ko)
*
|
2007-10-12 |
2016-07-20 |
시애틀 지네틱스, 인크. |
항체-약물 접합체를 이용한 병용 요법
|
|
WO2010081004A1
(en)
|
2009-01-09 |
2010-07-15 |
Seattle Genetics, Inc. |
Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
|
|
KR20210090298A
(ko)
*
|
2012-10-30 |
2021-07-19 |
에스퍼란스 파마슈티컬스, 인코포레이티드 |
항체/약물 컨쥬게이트 및 이의 사용 방법
|
|
EP3404024B1
(en)
*
|
2016-01-14 |
2020-11-18 |
Kangpu Biopharmaceuticals, Ltd. |
Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications
|
|
SG11201808625QA
(en)
*
|
2016-04-04 |
2018-10-30 |
Chemocentryx Inc |
SOLUBLE C5aR ANTAGONISTS
|
|
SG11201908520TA
(en)
*
|
2017-03-14 |
2019-10-30 |
Shimadzu Corp |
Method for simultaneous quantification of monoclonal antibodies
|
|
EP3744719B1
(en)
*
|
2018-01-25 |
2023-06-07 |
Fujimoto Co., Ltd. |
Thiophene derivative and use thereof
|
|
EP3752190B1
(en)
*
|
2018-02-12 |
2022-07-06 |
Forty Seven, Inc. |
Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
|